CELLINK AB announces the completion of the offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an overall amount of SEK 3.0 billion Erik Gatenholm, CEO Phone (Sweden): +46 70 991 86 04 Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138 Email: eg@cellink.com Email: gd@cellink.com This is information that CELLINK AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above at 01.30 CET on 12 March 2021. About CELLINK Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK's products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,600 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq Stockholm under CLNK B. www.cellink.com/investors